丙戊酸钠,1069-66-5，生产厂家，价格-洛克化工网移动版

返回



基本信息

制备方法及用途

物化性质

安全信息

毒理性

MSDS

海关数据

结构与计算化学

上游产品

下游产品

丙戊酸钠

中文名称：: 丙戊酸钠

中文别名：: 丙戊酸钠;
2-丙基戊酸钠;
敌白痉

英文名称：: Pentanoic acid,2-propyl-, sodium salt (1:1)

英文别名：: sodium valproate;
sodium,2-propylpentanoate;
2-Propylpentanoic acid,sodium salt;
Sodium 2-Propylvalerate;
Sodium 2-Propylpentanoate;
Sodium 2-propylpentanoate;
Sodium Valproate;
2-Propylvaleric Acid Sodium Salt;
2-Propylpentanoic Acid Sodium Salt;
2-Propylpentanoic acid;
Valproic Acid Sodium Salt

CAS No.：: 1069-66-5

分子式：: C₈H₁₆O₂.Na

分子量：: 166.19

精确分子量：: 166.09700

PSA：: 40.13000

MDL：: MFCD00078604

EINECS：: 213-961-8

InChI：: InChI=1/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-13

危险品标志：: T

风险术语：: R22;R36/38;R61

安全术语：: S26;S37/39;S45;S53

分子结构式：

SDS：: 查看

丙戊酸钠毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :: YV7876000

CHEMICAL NAME :: Valeric acid, 2-propyl-, sodium salt

CAS REGISTRY NUMBER :: 1069-66-5

LAST UPDATED :: 199801

DATA ITEMS CITED :: 66

MOLECULAR FORMULA :: C8-H15-O2.Na

MOLECULAR WEIGHT :: 166.22

WISWESSER LINE NOTATION :: OVY3&Y1&1 &-NA-

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 214 mg/kg/30D-I

TOXIC EFFECTS :: Skin and Appendages - dermatitis, allergic (after systemic exposure)

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 250 mg/kg/10D-I

TOXIC EFFECTS :: Gastrointestinal - changes in structure or function of endocrine pancreas Blood - hemorrhage

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 750 mg/kg

TOXIC EFFECTS :: Behavioral - coma Cardiac - other changes Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Behavioral - sleep Behavioral - muscle weakness

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 1820 mg/kg/12W-I

TOXIC EFFECTS :: Behavioral - sleep Gastrointestinal - nausea or vomiting Nutritional and Gross Metabolic - dehydration

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 17 mg/kg

TOXIC EFFECTS :: Brain and Coverings - other degenerative changes Behavioral - muscle contraction or spasticity Liver - liver function tests impaired

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 670 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 970 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1029 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 509 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 977 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 470 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - tremor Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 860 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - tremor Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 750 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - tremor Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 832 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 1420 mg/kg

TOXIC EFFECTS :: Behavioral - tremor Behavioral - ataxia Gastrointestinal - nausea or vomiting

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 700 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - tremor Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 565 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 1468 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 1200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 824 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - tremor Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - hamster

DOSE/DURATION :: 1740 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - tremor Behavioral - ataxia

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 72800 mg/kg/1Y-I

TOXIC EFFECTS :: Brain and Coverings - other degenerative changes Vascular - structural changes in vessels

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 109 gm/kg/13W-C

TOXIC EFFECTS :: Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in other cell count (unspecified) Related to Chronic Data - changes in testicular weight

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 97200 mg/kg/26W-I

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - ataxia Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 25280 mg/kg/21D-C

TOXIC EFFECTS :: Liver - other changes Kidney, Ureter, Bladder - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 9500 mg/kg/30D-I

TOXIC EFFECTS :: Behavioral - food intake (animal) Behavioral - muscle weakness Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 58500 mg/kg/90D-I

TOXIC EFFECTS :: Behavioral - food intake (animal) Behavioral - muscle weakness Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1620 mg/kg

SEX/DURATION :: female 1-39 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - hepatobiliary system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2700 mg/kg

SEX/DURATION :: female 1-39 week(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2700 mg/kg

SEX/DURATION :: female 1-39 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - hepatobiliary system Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - biochemical and metabolic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2800 mg/kg

SEX/DURATION :: female 7-13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3 gm/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 5904 mg/kg

SEX/DURATION :: female 7-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 5904 mg/kg

SEX/DURATION :: female 7-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 1950 mg/kg

SEX/DURATION :: female 7-9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 900 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 900 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1350 mg/kg

SEX/DURATION :: female 7-12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 750 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3360 mg/kg

SEX/DURATION :: female 7-12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1400 mg/kg

SEX/DURATION :: female 7-13 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 201 mg/kg

SEX/DURATION :: female 8-10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 600 mg/kg

SEX/DURATION :: female 7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 464 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 340 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 400 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 90 mg/kg

SEX/DURATION :: female 3 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - other effects to embryo

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 3600 mg/kg

SEX/DURATION :: female 7-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 450 mg/kg

SEX/DURATION :: female 7-8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 300 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 600 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Implant

DOSE :: 490 mg/kg

SEX/DURATION :: female 7-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 464 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 6 gm/kg

SEX/DURATION :: female 21-31 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 6 gm/kg

SEX/DURATION :: female 22-31 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3 gm/kg

SEX/DURATION :: female 21-50 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 6 gm/kg

SEX/DURATION :: female 21-50 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2600 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 4095 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 5200 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 4550 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Human Lymphocyte

DOSE/DURATION :: 5 mg/L

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 243,63,1990 *** REVIEWS *** TOXICOLOGY REVIEW DRUGAY Drugs. International Journal of Current Therapeutics and Applied Pharmacology Reviews. (ADIS Press International Inc., Suite B-30, Oxford Ct. Business Center, 582 Middletown Blvd., Langhorne, PA 19047) V.1- 1971- Volume(issue)/page/year: 13,81,1977 TOXICOLOGY REVIEW PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,58,1979

丙戊酸钠 MSDS

模块 1. 化学品
  1.1 产品标识符
    : Valproic acid sodium salt
    产品名称
  1.2 鉴别的其他方法
    Sodium valproate
    Sodium 2-propylpentanoate
    2-propylpentanoic acidsodium
  1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
    仅用于研发。不作为药品、家庭或其它用途。

模块 2. 危险性概述
  2.1 GHS-分类
    急性毒性, 经口 (类别 4)
  2.2 GHS 标记要素，包括预防性的陈述
    象形图
    警示词        警告
    危险申明
    H302        吞咽有害。
    警告申明
    预防措施
    P264        操作后彻底清洁皮肤。
    P270        使用本产品时不要进食、饮水或吸烟。
    事故响应
    P301 + P312        如果吞咽并觉不适: 立即呼叫解毒中心或就医。
    P330        漱口。
    废弃处置
    P501        将内容物/ 容器处理到得到批准的废物处理厂。
  2.3 其它危害物 - 无

模块 3. 成分/组成信息
  3.1 物质
    : Sodium valproate
    别名
    Sodium 2-propylpentanoate
    2-propylpentanoic acidsodium
    : C8H15NaO2
    分子式
    : 166.19 g/mol
    分子量
    组分        浓度或浓度范围
    Sodium valproate
    <=100%
    化学文摘登记号(CAS        1069-66-5
    No.)        213-961-8
    EC-编号

模块 4. 急救措施
  4.1 必要的急救措施描述
    一般的建议
    请教医生。向到现场的医生出示此安全技术说明书。
    吸入
    如果吸入,请将患者移到新鲜空气处。如呼吸停止,进行人工呼吸。请教医生。
    皮肤接触
    用肥皂和大量的水冲洗。请教医生。
    眼睛接触
    用水冲洗眼睛作为预防措施。
    食入
    切勿给失去知觉者通过口喂任何东西。用水漱口。请教医生。
  4.2 主要症状和影响，急性和迟发效应
    嗜睡, 虚弱, 嗜睡, 皮疹, 秃头症, 消化系统失调, 运动失调
  4.3 及时的医疗处理和所需的特殊处理的说明和指示
    无数据资料

模块 5. 消防措施
  5.1 灭火介质
    灭火方法及灭火剂
    用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。
  5.2 源于此物质或混合物的特别的危害
    碳氧化物, 氧化钠
  5.3 给消防员的建议
    如必要的话,戴自给式呼吸器去救火。
  5.4 进一步信息
    无数据资料

模块 6. 泄露应急处理
  6.1 作业人员防护措施、防护装备和应急处置程序
    使用个人防护用品。避免粉尘生成。避免吸入蒸气、烟雾或气体。保证充分的通风。避免吸入粉尘。
  6.2 环境保护措施
    不要让产品进入下水道。
  6.3 泄漏化学品的收容、清除方法及所使用的处置材料
    收集和处置时不要产生粉尘。扫掉和铲掉。放入合适的封闭的容器中待处理。
  6.4 参考其他部分
    丢弃处理请参阅第13节。

模块 7. 操作处置与储存
  7.1 安全操作的注意事项
    避免接触皮肤和眼睛。避免形成粉尘和气溶胶。
    在有粉尘生成的地方,提供合适的排风设备。一般性的防火保护措施。
  7.2 安全储存的条件,包括任何不兼容性
    贮存在阴凉处。使容器保持密闭，储存在干燥通风处。
  7.3 特定用途
    无数据资料

模块 8. 接触控制和个体防护
  8.1 容许浓度
    最高容许浓度
    没有已知的国家规定的暴露极限。
  8.2 暴露控制
    适当的技术控制
    根据良好的工业卫生和安全规范进行操作。休息前和工作结束时洗手。
    个体防护设备
    眼/面保护
    带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟)
    检测与批准的设备防护眼部。
    皮肤保护
    戴手套取手套在使用前必须受检查。
    请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
    使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
    所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
    完全接触
    物料: 丁腈橡胶
    最小的层厚度 0.11 mm
    溶剂渗透时间: 480 min
    测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
    飞溅保护
    物料: 丁腈橡胶
    最小的层厚度 0.11 mm
    溶剂渗透时间: 480 min
    测试过的物质Dermatril® (KCL 740 / Z677272, 规格 M)
,     测试方法 EN374
    如果以溶剂形式应用或与其它物质混合应用，或在不同于EN
    374规定的条件下应用，请与EC批准的手套的供应商联系。
    这个推荐只是建议性的,并且务必让熟悉我们客户计划使用的特定情况的工业卫生学专家评估确认才可.
    这不应该解释为在提供对任何特定使用情况方法的批准.
    身体保护
    全套防化学试剂工作服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。
    呼吸系统防护
    如须暴露于有害环境中,请使用P95型(美国)或P1型(欧盟英国
    143)防微粒呼吸器。如需更高级别防护,请使用OV/AG/P99型(美国)或ABEK-P2型 (欧盟英国 143)
    防毒罐。
    呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。

模块 9. 理化特性
  9.1 基本的理化特性的信息
    a) 外观与性状
    形状: 固体
    b) 气味
    无数据资料
    c) 气味阈值
    无数据资料
    d) pH值
    无数据资料
    e) 熔点/凝固点
    无数据资料
    f) 沸点、初沸点和沸程
    无数据资料
    g) 闪点
    无数据资料
    h) 蒸发速率
    无数据资料
    i) 易燃性(固体,气体)
    无数据资料
    j) 高的/低的燃烧性或爆炸性限度无数据资料
    k) 蒸气压
    无数据资料
    l) 蒸汽密度
    无数据资料
    m) 密度/相对密度
    无数据资料
    n) 水溶性
    无数据资料
    o) n-辛醇/水分配系数
    辛醇--水的分配系数的对数值: 2.603
    p) 自燃温度
    无数据资料
    q) 分解温度
    无数据资料
    r) 粘度
    无数据资料

模块 10. 稳定性和反应活性
  10.1 反应性
    无数据资料
  10.2 稳定性
    无数据资料
  10.3 危险反应
    无数据资料
  10.4 应避免的条件
    无数据资料
  10.5 不相容的物质
    强氧化剂
  10.6 危险的分解产物
    其它分解产物 - 无数据资料

模块 11. 毒理学资料
  11.1 毒理学影响的信息
    急性毒性
    半数致死剂量 (LD50) 经口 - 大鼠 - 670 mg/kg
    皮肤刺激或腐蚀
    无数据资料
    眼睛刺激或腐蚀
    无数据资料
    呼吸道或皮肤过敏
    无数据资料
    生殖细胞致突变性
    无数据资料
    致癌性
    IARC:
    此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
    生殖毒性
    无数据资料
    特异性靶器官系统毒性（一次接触）
    无数据资料
    特异性靶器官系统毒性（反复接触）
    无数据资料
    吸入危险
    无数据资料
    潜在的健康影响
    吸入        吸入可能有害。可能引起呼吸道刺激。
    摄入        误吞对人体有害。
    皮肤        通过皮肤吸收可能有害。可能引起皮肤刺激。
    眼睛        可能引起眼睛刺激。
    接触后的征兆和症状
    嗜睡, 虚弱, 嗜睡, 皮疹, 秃头症, 消化系统失调, 运动失调
    附加说明
    化学物质毒性作用登记: YV7876000

模块 12. 生态学资料
  12.1 生态毒性
    无数据资料
  12.2 持久性和降解性
    无数据资料
  12.3 潜在的生物累积性
    无数据资料
  12.4 土壤中的迁移性
    无数据资料
  12.5 PBT 和 vPvB的结果评价
    无数据资料
  12.6 其它不良影响
    无数据资料

模块 13. 废弃处置
  13.1 废物处理方法
    产品
    将剩余的和不可回收的溶液交给有许可证的公司处理。
    联系专业的拥有废弃物处理执照的机构来处理此物质。
    与易燃溶剂相溶或者相混合，在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧
    受污染的容器和包装
    按未用产品处置。

模块 14. 运输信息
  14.1 联合国危险货物编号
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.2 联合国运输名称
    欧洲陆运危规: 非危险货物
    国际海运危规: 非危险货物
    国际空运危规: 非危险货物
  14.3 运输危险类别
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.4 包裹组
    欧洲陆运危规: -        国际海运危规: -        国际空运危规: -
  14.5 环境危险
    欧洲陆运危规: 否        国际海运危规        国际空运危规: 否
    海洋污染物（是/否）: 否
  14.6 对使用者的特别提醒
    无数据资料
    上述信息视为正确，但不包含所有的信息，仅作为指引使用。本文件中的信息是基于我们目前所知，就正
    确的安全提示来说适用于本品。该信息不代表对此产品性质的保证。
    参见发票或包装条的反面。

模块 15 - 法规信息
N/A

模块16 - 其他信息
N/A